Literatur zu Certolizumab Pegol (Cimzia)

Klinische Studien:

Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA.
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
Rheumatology 2002 Oct;41(10):1133-7
Abstract
Volltext

Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V.
Efficacy and safety of certolizumab Pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
Ann Rheum Dis. 2009 Jun;68(6):805-11. Epub 2008 Nov 17.
Abstract
Volltext

Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven RF.
Effect of certolizumab Pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum. 2009 Nov 15;61(11):1592-600.

Keystone E, Heijde D, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K.
Certolizumab Pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Arthritis Rheum. 2008 Nov;58(11):3319-29                     
Abstract
Volltext

Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D.
Efficacy and safety of certolizumab Pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Ann Rheum Dis. 2009 Jun;68(6):797-804. Epub 2008 Nov 17
Abstract
Volltext

Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A.
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab Pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Arthritis Res Ther. 2009 Nov 12;11(6):R170. [Epub ahead of print]
Abstract
Volltext